Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Ocugen ( (OCGN) ).
On January 22–23, 2026, Ocugen, Inc. closed an underwritten registered direct offering of 15,000,000 shares of common stock at $1.50 per share, raising $22.5 million in gross proceeds and approximately $20.85 million in net proceeds after commissions and expenses. Led by RTW Investments with participation from new and existing investors, and managed by Oppenheimer & Co. as sole bookrunner, the capital raise is intended to fund general corporate purposes, capital expenditures, working capital, and administrative costs, and is expected to extend the company’s cash runway into the fourth quarter of 2026, bolstering its financial position as it advances its pipeline of gene therapies for blindness diseases.
The most recent analyst rating on (OCGN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.
Spark’s Take on OCGN Stock
According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.
The score is held down primarily by weak financial performance (losses, high leverage, and cash flow strain). Technicals and recent clinical/program updates are supportive and provide upside potential, but valuation remains constrained by lack of profitability.
To see Spark’s full report on OCGN stock, click here.
More about Ocugen
Ocugen, Inc., based in Malvern, Pa., is a biotechnology company specializing in gene therapies for blindness diseases. Leveraging a modifier gene therapy platform with a gene‑agnostic approach, it is developing treatments for inherited retinal disorders and other vision-threatening conditions such as retinitis pigmentosa, Stargardt disease, and geographic atrophy associated with late-stage dry age-related macular degeneration, targeting large patient populations with significant unmet medical need.
Average Trading Volume: 4,376,702
Technical Sentiment Signal: Hold
Current Market Cap: $521.6M
For detailed information about OCGN stock, go to TipRanks’ Stock Analysis page.